vs
UiPath, Inc.（PATH）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Bio-Techne的1.4倍（$411.1M vs $295.9M），UiPath, Inc.净利率更高（48.4% vs 12.8%，领先35.5%），UiPath, Inc.同比增速更快（15.9% vs -6.4%），过去两年Bio-Techne的营收复合增速更高（4.2% vs 0.7%）
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
PATH vs TECH — 直观对比
营收规模更大
PATH
是对方的1.4倍
$295.9M
营收增速更快
PATH
高出22.3%
-6.4%
净利率更高
PATH
高出35.5%
12.8%
两年增速更快
TECH
近两年复合增速
0.7%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $411.1M | $295.9M |
| 净利润 | $198.8M | $38.0M |
| 毛利率 | 83.3% | 64.6% |
| 营业利润率 | 3.2% | 18.4% |
| 净利率 | 48.4% | 12.8% |
| 营收同比 | 15.9% | -6.4% |
| 净利润同比 | 1966.2% | 68.3% |
| 每股收益（稀释后） | $0.37 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PATHTECH
| Q4 25 | $411.1M | $295.9M | ||
| Q3 25 | $361.7M | — | ||
| Q2 25 | $356.6M | $317.0M | ||
| Q1 25 | $423.6M | $316.2M | ||
| Q4 24 | $354.7M | $297.0M | ||
| Q3 24 | $316.3M | $289.5M | ||
| Q2 24 | $335.1M | $306.1M | ||
| Q1 24 | $405.3M | $303.4M |
净利润PATHTECH
| Q4 25 | $198.8M | $38.0M | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $-22.6M | $-17.7M | ||
| Q1 25 | $51.8M | $22.6M | ||
| Q4 24 | $-10.7M | $34.9M | ||
| Q3 24 | $-86.1M | $33.6M | ||
| Q2 24 | $-28.7M | $40.6M | ||
| Q1 24 | $33.9M | $49.1M |
毛利率PATHTECH
| Q4 25 | 83.3% | 64.6% | ||
| Q3 25 | 82.2% | — | ||
| Q2 25 | 82.1% | 62.7% | ||
| Q1 25 | 84.8% | 67.9% | ||
| Q4 24 | 82.0% | 65.3% | ||
| Q3 24 | 80.0% | 63.2% | ||
| Q2 24 | 83.5% | 66.4% | ||
| Q1 24 | 86.8% | 67.4% |
营业利润率PATHTECH
| Q4 25 | 3.2% | 18.4% | ||
| Q3 25 | -5.6% | — | ||
| Q2 25 | -4.6% | -7.5% | ||
| Q1 25 | 7.9% | 12.2% | ||
| Q4 24 | -12.2% | 16.0% | ||
| Q3 24 | -32.7% | 13.8% | ||
| Q2 24 | -14.8% | 15.0% | ||
| Q1 24 | 3.7% | 22.1% |
净利率PATHTECH
| Q4 25 | 48.4% | 12.8% | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | -6.3% | -5.6% | ||
| Q1 25 | 12.2% | 7.1% | ||
| Q4 24 | -3.0% | 11.7% | ||
| Q3 24 | -27.2% | 11.6% | ||
| Q2 24 | -8.6% | 13.3% | ||
| Q1 24 | 8.4% | 16.2% |
每股收益（稀释后）PATHTECH
| Q4 25 | $0.37 | $0.24 | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.04 | $-0.11 | ||
| Q1 25 | $0.09 | $0.14 | ||
| Q4 24 | $-0.02 | $0.22 | ||
| Q3 24 | $-0.15 | $0.21 | ||
| Q2 24 | $-0.05 | $0.26 | ||
| Q1 24 | $0.07 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $1.9B | $2.0B |
| 总资产 | $2.9B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资PATHTECH
| Q4 25 | $1.4B | $172.9M | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.6B | $162.2M | ||
| Q1 25 | $1.6B | $140.7M | ||
| Q4 24 | $1.6B | $177.5M | ||
| Q3 24 | $1.7B | $187.5M | ||
| Q2 24 | $1.9B | $152.9M | ||
| Q1 24 | $1.9B | $145.3M |
总债务PATHTECH
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
股东权益PATHTECH
| Q4 25 | $1.9B | $2.0B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.8B | $2.0B | ||
| Q4 24 | $1.7B | $2.1B | ||
| Q3 24 | $1.8B | $2.1B | ||
| Q2 24 | $2.0B | $2.1B | ||
| Q1 24 | $2.0B | $2.0B |
总资产PATHTECH
| Q4 25 | $2.9B | $2.5B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.9B | $2.6B | ||
| Q4 24 | $2.7B | $2.7B | ||
| Q3 24 | $2.7B | $2.7B | ||
| Q2 24 | $2.8B | $2.7B | ||
| Q1 24 | $3.0B | $2.7B |
负债/权益比PATHTECH
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | — |
| 自由现金流经营现金流 - 资本支出 | $25.1M | — |
| 自由现金流率自由现金流/营收 | 6.1% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.14× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PATHTECH
| Q4 25 | $28.3M | — | ||
| Q3 25 | $41.6M | — | ||
| Q2 25 | $119.0M | $98.2M | ||
| Q1 25 | $146.1M | $41.1M | ||
| Q4 24 | $28.1M | $84.3M | ||
| Q3 24 | $46.4M | $63.9M | ||
| Q2 24 | $100.0M | $75.5M | ||
| Q1 24 | $145.6M | $81.0M |
自由现金流PATHTECH
| Q4 25 | $25.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $106.2M | $93.3M | ||
| Q1 25 | $138.7M | $31.0M | ||
| Q4 24 | $23.2M | $77.5M | ||
| Q3 24 | $45.0M | $54.7M | ||
| Q2 24 | $98.8M | $57.5M | ||
| Q1 24 | $141.8M | $64.5M |
自由现金流率PATHTECH
| Q4 25 | 6.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 29.8% | 29.4% | ||
| Q1 25 | 32.7% | 9.8% | ||
| Q4 24 | 6.5% | 26.1% | ||
| Q3 24 | 14.2% | 18.9% | ||
| Q2 24 | 29.5% | 18.8% | ||
| Q1 24 | 35.0% | 21.3% |
资本支出强度PATHTECH
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 3.6% | 1.5% | ||
| Q1 25 | 1.7% | 3.2% | ||
| Q4 24 | 1.4% | 2.3% | ||
| Q3 24 | 0.4% | 3.2% | ||
| Q2 24 | 0.4% | 5.9% | ||
| Q1 24 | 0.9% | 5.4% |
现金转化率PATHTECH
| Q4 25 | 0.14× | — | ||
| Q3 25 | 26.25× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.82× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | 4.29× | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
